EGFR and non-small cell lung carcinoma: There were 27 EGFR-WT NSCLC patients receiving ICIs treatment from GSE13522, and the YAP1_High group had no different PFS with the YAP1_Low group (1.8 months vs 2.4 months, P=0.894, Figure 6(c)).